INFO LE FIGARO – The pharmacy giant’s board of directors received a new offer this morning. This is valid until Sunday evening.
Development in the case of the sale of Doliprane Sanofi. Announced last Friday, the pharmacy giant’s plan to cede control of Opella, its subsidiary dedicated to medicines sold without a prescription, to the American investment fund CD&R, has sparked an outcry in parliament and among Sanofi unions, who called a renewable strike starting this Thursday.
PAI Partners, whose offer was not accepted by the Sanofi board of directors last week, took advantage of this tense context to return to the race. According to our information, the Paris-based investment fund sent a revised offer this morning to Frédéric Oudéa, the chairman of the group’s board of directors. In this letter, that Le Figaro was able to consult, PAI raises the price proposed last week by 200 million euros. Enough to find yourself better financially than CD&R.
Also read
“It’s always the same story”: what the excitement surrounding the sale of Doliprane to the American fund CD&R reveals
Above all, the new offer from PAI Partners seems to meet most of the guarantees…
This article is reserved for subscribers. You have 64% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
